Sponsor content

Original approach to multidrug-resistant tuberculosis

Qurient is poised to put Q203, a first-in-class drug candidate that targets multidrug-resistant tuberculosis, in phase 2 testing by the end of 2017, and is now looking for a partner.

Go to the profile of Qurient Co., Ltd.
Jun 06, 2017
0
0
Upvote 0 Comment
Page of
Go to the profile of Qurient Co., Ltd.

Qurient Co., Ltd.

Qurient is a ‘Network R&D company’ mainly focuses on development of novel therapeutics from late discovery to human proof of concept. Qurient has expertise in virtual R&D project management and operates through extensive network of research organizations.

No comments yet.